Apigenin loaded lipoid-plga-tpgs nanoparticles for colon cancer therapy: characterization, sustained release, cytotoxicity, and apoptosis pathways

HIGHLIGHTS

  • who: Mohamed A. Alfaleh and collaborators from the Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia have published the research: Apigenin Loaded Lipoid-PLGA-TPGS Nanoparticles for Colon Cancer Therapy: Characterization, Sustained Release, Cytotoxicity, and Apoptosis Pathways, in the Journal: Polymers 2022, 14, 3577. of /2022/
  • what: One of the major reasons for the drug resistance in the CC is the increased expression of the multidrug resistance (MDR1) gene. The authors designed and developed an apigenin (AGN) hybrid nanoparticle (HyNP) to manage and treat CC. This study was designed with novelty . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?